Editas Medicine, Inc.

EDITSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1650664

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$32.3M	$19.7M	$25.5M	$90.7M	$20.5M
Research and Development Expense	$199.2M	$175.0M	$142.5M	$158.0M	$96.9M
Operating Expenses	$283.5M	$245.7M	$218.7M	$225.6M	$161.5M
Operating Income (Loss)	-$251.2M	-$225.9M	-$193.1M	-$134.8M	-$140.9M
Nonoperating Income (Expense)	$14.1M	$5.5M	$644.0K	$18.9M	$7.2M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	—
Net Income (Loss) Attributable to Parent	-$237.1M	-$220.4M	-$192.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$341.6M	$499.2M	$514.3M	$677.5M	$572.6M
Assets, Current	$289.3M	$340.8M	$356.8M	$507.3M	$419.1M
Cash and Cash Equivalents, at Carrying Value	$131.5M	$141.5M	$141.5M	$203.5M	$139.7M
Liabilities	$207.3M	$150.1M	$153.6M	$123.8M	$179.0M
Liabilities, Current	$77.2M	$63.2M	$60.1M	$46.9M	$58.2M
Long-term Debt	—	$57.4M	—	—	—
Accounts Payable, Current	$5.5M	$8.3M	$9.5M	$5.0M	$6.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$210.3M	-$177.3M	-$163.8M	-$179.8M	-$40.7M
Net Cash Provided by (Used in) Investing Activities	$162.1M	$114.1M	-$54.5M	-$140.5M	$12.3M
Net Cash Provided by (Used in) Financing Activities	$56.0M	$1.3M	$282.1M	$224.1M	$131.8M
Payments to Acquire Property, Plant, and Equipment	$8.8M	$4.1M	$8.0M	$7.2M	$6.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)